The p38 alpha inhibitor Neflamapimod was clinically successful in the treatment of Stage II of Louisian dementia, and patients' cognition improved significantly.

At the 13th Clinical Trials (CTAD) of Alzheimer's Disease, EIP Pharmaceuticals announced that the central nervous system disease drug Neflamapimod (VX745) is treating patients with mild to moderate Louisian dementia (DLB), with Phase II trials reaching the primary endpoint.
a set of neuropsytherapy tests (NTB) assessments showed significant improvements in cognitive abilities in patients treated with Neflamapimod three times a day.
addition, several secondary clinical endpoints have also achieved significant statistical improvements.
in the double-blind placebo-controlled AscenD-LB study, 91 patients were randomly assigned 40 mg of Neflamapimod capsules or placebos at 1:1.
patients treated with Neflamapimod showed significant cognitive improvement and good tolerance compared to those in the placebo group.
based on Phase II research, the company plans to advance the development of neflamapimod to Phase III clinical.
: Neflamapimod is a small molecular drug that penetrates the brain and inhibits in-cell enzyme p38 MAP kinase α (p38 alpha).
P38 alpha is expressed in neurons under stress and disease conditions and is known to play a major role in inflammation-induced synaptic toxicity, leading to impaired synapse function.
synapse dysfunction can cause cognitive impairment in a variety of central nervous system diseases, including DLB and Alzheimer's disease.
Neflamapimod was approved by the U.S. Food and Drug Administration (FDA) as a DLB treatment in November 2019.
.